Interpace Pharma Solutions: RNAscope ISH

Interpace Pharma solutions, a subsidiary of Interpace Biosciences has launched its RNAscope in situ hybridization (ISH) assay. The firm said RNAscope ISH uses "double Z" probes that simultaneously offer signal amplification and background noise control. Single-molecule visualization of the assay produces quantitative RNA expression and cell-specific expression in intact tissue architecture. The firm said that RNAscope ISH can be used to streamline immune checkpoint target identification, visualize in vivo delivery of CAR-T therapeutic products, and distinguish therapeutic gene sequence from endogenous transcripts selection, even when there is no known or validated antibody.